X

This is not a paywall.

Register for free to continue reading.

We made a promise to you that we’ll never erect a paywall and we intend to keep that promise. We also want to continually improve your reading experience and you can help us do that by registering with us. It’s quick, easy and will cost you nothing.



Nearly there! Create a password to finish up registering with us:


Please enter your password or get a login link if you’ve forgotten


Open Sesame! Thanks for registering.

First Thing, Daily Maverick's flagship newsletter

Join the 230 000 South Africans who read First Thing newsletter.

We'd like our readers to start paying for Daily Maverick

More specifically, we'd like those who can afford to pay to start paying. What it comes down to is whether or not you value Daily Maverick. Think of us in terms of your daily cappuccino from your favourite coffee shop. It costs around R35. That’s R1,050 per month on frothy milk. Don’t get us wrong, we’re almost exclusively fuelled by coffee. BUT maybe R200 of that R1,050 could go to the journalism that’s fighting for the country?

We don’t dictate how much we’d like our readers to contribute. After all, how much you value our work is subjective (and frankly, every amount helps). At R200, you get it back in Uber Eats and ride vouchers every month, but that’s just a suggestion. A little less than a week’s worth of cappuccinos.

We can't survive on hope and our own determination. Our country is going to be considerably worse off if we don’t have a strong, sustainable news media. If you’re rejigging your budgets, and it comes to choosing between frothy milk and Daily Maverick, we hope you might reconsider that cappuccino.

We need your help. And we’re not ashamed to ask for it.

Our mission is to Defend Truth. Join Maverick Insider.

Support Daily Maverick→
Payment options

Pfizer Projects $15 Billion in 2021 Sales of Covid Vacc...

Business Maverick

Business Maverick

Pfizer Projects $15 Billion in 2021 Sales of Covid Vaccine

A vial of the the Pfizer-BioNTech Covid-19 vaccine. (Photo: Supplied)
By Bloomberg
03 Feb 2021 0

Pfizer Inc. projected about $15 billion in revenue this year from the Covid-19 vaccine it developed with BioNTech SE, but the shares fell amid questions about the durability of the market for the shot.

Company officials led by Chief Executive Albert Bourla said on a conference call that the vaccine looks capable of taking on new variants, its price may increase and new products using its messenger RNA technology are on the way. Still, the shares fell as much as 4.3% and were down 2.2% at 2:10 p.m Tuesday in New York.

The first of the Western coronavirus shots cleared for use, the Pfizer-BioNTech vaccine will soon face competition from more entrants, including from Johnson & Johnson and Novavax Inc. that are poised for authorization. New virus variants may also require additional vaccines or reformulated booster shots for protection.

Pfizer’s position in the Covid-19 vaccine market may be difficult to sustain over time, said JPMorgan analyst Christopher Schott. Investors need to see further de-risking of Pfizer’s pipeline to support growth, he said in a note to investors.

What Bloomberg Intelligence Says

“We believe the view on operating margin is unnerving. Sales expectations of $59.4-$61.4 billion are $4 billion higher than consensus at the midpoint, with Covid-19 vaccine sales expected at $15 billion vs. consensus for $11 billion. The midpoint EPS goal of $3.15 is slightly below views, due to much lower gross margin and higher R&D costs.”

— Pharma analysts Michael Shah and Sam Fazeli

See the research here

Pfizer commands a higher price for its Covid-19 vaccine than some rivals. Under the terms of its supply deal with the U.S., it is charging $19.50 for each shot of the two-dose regimen. Meanwhile AstraZeneca Plc, which hasn’t yet gained U.S. authorization for its two-dose vaccine, has said it plans to charge less than $4 per shot, and J&J is aiming to price its single-shot vaccine at less than $10.

Pfizer’s vaccine sales projection primarily includes doses that are expected to be delivered this year under existing contracts, the company said as it reported fourth-quarter earnings.

Excluding those sales, Pfizer expects 2021 full-year revenue of $44.4 billion to $46.4 billion. Annual earnings per share will be $3.10 to $3.20. Bourla had said earlier this month that earnings would top out at $3.10 a share. The guidance was raised primarily because of the shifting vaccine outlook, according to the company.

Vaccine Sales

Based on mRNA technology that makes human cells into vaccine factories, the Pfizer-BioNTech shot was more than 90% effective in preventing Covid-19 symptoms in a late-stage clinical trial. It brought in $154 million in sales in the fourth quarter.

Drugmaker CEOs Testify Before Senate Finance Committee On Drug Pricing
Albert Bourla

Pfizer and Germany’s BioNTech initially expected to produce 1.3 billion doses of the vaccine, known BNT162b2, this year. They later boosted their output goal to 2 billion doses after a label change allowed doctors to extract six doses instead of five from each vial, and they secured additional manufacturing capacity. The boon to supply will likely add to the companies’ sales.

To date, Pfizer and BioNTech have reached agreements totaling 836 million doses, according to Bloomberg’s Vaccine Tracker, including 300 million for the EU and 200 million for the U.S. Though executives declined to comment on the underlying number of doses accounted for in the 2021 forecast, they suggested more agreements with governments could still come, likely leading to an even larger sales figure.

Read More: Pfizer to Deliver U.S. Vaccine Doses Faster Than Expected

If the market were open to all purchasers, not just governments, Pfizer would expect to have the lion’s share of demand “because we are first, and we are best,” Bourla said to investors. “But this is not an open market, at least for this year,” he added, tempering expectations that the company would be able to sell all 2 billion doses before year end.

“This market creates a lot of political pressures,” he said. “The decisions aren’t always made on science.”

Evercore ISI analyst Umer Raffat expects Pfizer to ultimately bring in more vaccine sales than it forecast Tuesday. “I do think the number is going to tick up,” he said in an interview.

The drugmaker may generate additional revenue from a booster shot it’s developing to combat a rapidly spreading variant that emerged in South Africa, according to Raffat.

Pfizer sees its vaccine as highly effective against variants because of the high levels of antibodies it raises. Still, the company aims to start a study comparing a third booster dose customized against a key mutation seen in the South Africa and Brazil strains that would be given six to 12 months after the first two doses. If booster shots continue to be needed after the pandemic is over, Pfizer will likely get a higher price for the vaccine, executives said.

Innovation-Focused

The drug giant’s overall fourth-quarter figures were anticipated to be messy following the spinoff of its off-patent drug unit, Upjohn, into a combined company with Mylan NV now known as Viatris Inc.

The new, slimmed-down Pfizer brought in $11.7 billion. Major blockbusters, including the cancer drug Ibrance, the anticoagulant Eliquis, and the Prevnar vaccine franchise drove much of the company’s growth.

Pfizer spent more than $9 billion on research and development, including on its pandemic response efforts, in 2020. Bourla cited the company’s “decade-long conversion into a pure-play, science and innovation-focused company,” for the company’s progress.

“Our record-breaking success at developing a vaccine against Covid-19, along with our partner BioNTech, is just one example of what we believe this new Pfizer is capable of achieving,” he said in the statement.

Gallery

Comments - share your knowledge and experience

Please note you must be a Maverick Insider to comment. Sign up here or sign in if you are already an Insider.

Everybody has an opinion but not everyone has the knowledge and the experience to contribute meaningfully to a discussion. That’s what we want from our members. Help us learn with your expertise and insights on articles that we publish. We encourage different, respectful viewpoints to further our understanding of the world. View our comments policy here.

No Comments, yet

Please peer review 3 community comments before your comment can be posted